Abstract Review Purpose This review summarises key findings on treatment effects within
phenotypical clusters of patients with heart failure (HF), making a distinction between …

Heart failure (HF) is the leading cause of mortality in patients with acute myocardial
infarction (AMI), with incidence ranging from 14% to 36% in patients admitted due to AMI. HF …

Aims Adrenomedullin is a vasodilatory peptide with a role in microcirculatory and
endothelial homeostasis. Adrenomedullin is a substrate for neprilysin and may therefore …

Background Patients who sustain an acute myocardial infarction (AMI), including ST-
segment elevation myocardial infarction (STEMI) and non–ST-segment elevation myocardial …

Abstract Effects of angiotensin receptor/neprilysin inhibitors (ARNI) on ventricular
remodeling in patients with heart failure, especially heart failure with reduced ejection …

BACKGROUND: Sacubitril/valsartan (Sac/Val) is superior to angiotensin-converting enzyme
inhibitors in reducing the risk of heart failure hospitalization and cardiovascular death, but its …

In patients with acute myocardial infarction (MI), heart failure (HF) is one of the most common
complications that is associated with a significant burden of mortality and healthcare …

Background Based on previous research, both dapagliflozin (DAPA) and sacubitril-valsartan
(S/V) improve the prognosis of patients with heart failure (HF). Our study aims to investigate …

Background We assessed left ventricular ejection fraction (LVEF) to compare the effects of
renin–angiotensin system inhibitors (RASI) in patients with non-ST-segment elevation …

Two seminal findings in 1981 transformed cardiology. The first was the finding that
recanalization of acutely occluded coronary arteries salvages myocardium 1—a seemingly …